GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cardiff Oncology Inc (NAS:CRDF) » Definitions » Future 3-5Y Total Revenue Growth Rate

CRDF (Cardiff Oncology) Future 3-5Y Total Revenue Growth Rate : -40.95 (As of Jul. 11, 2025)


View and export this data going back to 1997. Start your Free Trial

What is Cardiff Oncology Future 3-5Y Total Revenue Growth Rate?

Future 3-5Y Total Revenue Growth Rate is the average growth rate of total revenue estimates over a 3-year to 5-year period.

As of today, Cardiff Oncology's Future 3-5Y Total Revenue Growth Rate is -40.95.

Competitive Comparison of Cardiff Oncology's Future 3-5Y Total Revenue Growth Rate

For the Biotechnology subindustry, Cardiff Oncology's Future 3-5Y Total Revenue Growth Rate, along with its competitors' market caps and Future 3-5Y Total Revenue Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Cardiff Oncology's Future 3-5Y Total Revenue Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Cardiff Oncology's Future 3-5Y Total Revenue Growth Rate distribution charts can be found below:

* The bar in red indicates where Cardiff Oncology's Future 3-5Y Total Revenue Growth Rate falls into.


;
;

Cardiff Oncology  (NAS:CRDF) Future 3-5Y Total Revenue Growth Rate Explanation

Future 3-5Y Total Revenue Growth Rate is the growth rate of total revenue estimates over a 3-year to 5-year period. This data is provided directly by our trusted data vendors Refinitiv or Morningstar.

In situations where both vendors do not directly provide the growth rate data, we use the most recent annual revenue for the current year and estimated future revenue figures provided by the vendor to calculate the growth rate. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average total revenue estimates growth rate.

Cardiff Oncology Future 3-5Y Total Revenue Growth Rate Related Terms

Thank you for viewing the detailed overview of Cardiff Oncology's Future 3-5Y Total Revenue Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

Cardiff Oncology Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cardiff Oncology Inc (NAS:CRDF) » Definitions » Future 3-5Y Total Revenue Growth Rate
Comparable Companies
MDWD INBX IMAB OABI MNPR SCPH YMAB LCTX DSGN ACIU VRTX ASX:CSL REGN XKRX:207940 ALNY XBRU:UCB XBRU:ARGX ONC XKRX:068270 BNTX
Traded in Other Exchanges
XE7C:Germany XE7C:Germany
Address
11055 Flintkote Avenue, San Diego, CA, USA, 92121
Website
https://www.cardiffoncology.com
Cardiff Oncology Inc is a clinical-stage biotechnology company leveraging PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies across a range of cancers with the greatest unmet medical need. It is focusing on clinical programs in indications such as RAS-mutated metastatic colorectal cancer ("mCRC"), as well as in investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma ("mPDAC"), small cell lung cancer ("SCLC"), and triple negative breast cancer ("TNBC"). Geographically, the company only operates in the United States.
Executives
James E. Levine officer: Chief Financial Officer 55 CAMBRIDGE PARKWAY, 8TH FLOOR, CAMBRIDGE MA 02142
Renee P Tannenbaum director 9220 KIRBY DRIVE, SUITE 500, HOUSTON TX 77054
Gary W Pace director C/O RESMED INC, 14040 DANIELSON STREET, POWAY CA 92064-6857
Fairooz Kabbinavar officer: Chief Medical Officer C/O TOCAGEN INC., 4242 CAMPUS POINT COURT, STE. 500, SAN DIEGO CA 92121
Mark Erlander officer: Chief Scientific Officer C/O TROVAGENE, INC., 11055 FLINTKOTE AVENUE, SUITE A, SAN DIEGO CA 92121
Lale White director 310 GODDARD, SUITE 150, IRVINE CA 92618
James O Armitage director C/O TESARO, INC., 1000 WINTER ST., SUITE 3300, WALTHAM MA 02451
Tod Smeal officer: Chief Scientific Officer 11055 FLINTKOTE AVENUE, SA DIEGO CA 92121
Katherine L Ruffner officer: Chief Medical Officer 11055 FLINTKOTE AVENUE, SAN DIEGO CA 92121
Mani Mohindru director C/O CARA THERAPEUTICS, INC., 4 STAMFORD PLAZA, 107 ELM STREET, STAMFORD CT 06902
Rodney S Markin director C/O UNIVERSITY OF NEBR MEDICAL CENTER, 983135 NEBRASKA MEDICAL CENTER, OMAHA NE 68198-3135
Gary S Jacob director
Vicki Kelemen officer: Exec. VP and COO 11055 FLINTKOTE AVENUE, SAN DIEGO CA 92121
John P Brancaccio director C/O TAMIR BIOTECHNOLOGY, INC., 11 DEER PARK DRIVE, SUITE 204, MONMOUTH JUNCTION NJ 08852
Rajeev M. Shah 10 percent owner 200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116